Veterans Suffering with Chronic Psychiatric Symptoms Should Seek Screening for Mefloquine Exposure

Originally developed by scientists working in affiliation with the Walter Reed Army Institute of Research (WRAIR), mefloquine was licensed by the FDA in 1989 and was sold as the branded medication Lariam from 1989 to 2011. Mefloquine is an antimalarial drug associated with the risk of chronic neuropsychiatric adverse effects (AEs). For the treatment of...
Read More

Private Health Care Options, Including Urgent Care, Now Available to Veterans with Disability Benefits

On June 6, 2019, the MISSION (Maintaining Internal Systems and Strengthening Integrated Outside Networks) Act went into effect, providing service members with additional health care options and increasing the number of veterans who may qualify for private care through the Department of Veterans Affairs (VA). The MISSION Act, which was signed into law one year...
Read More